semaj83/ctmatch_classification huggingface dataset:
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Spondylitis, Ankylosing Arthritis, Rheumatoid Psoriasis Arthritis, Psoriatic Participants with ankylosing spondylitis who did not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation Participants with rheumatoid arthritis who show insufficient response to disease modifying antirheumatic drug (DMARD) including methotrexate Participants with serious, active and progressive disease not previously treated with methotrexate or other DMARD Participant with moderate to serious plaque psoriasis who are unresponsive, contra indicant or intolerable to the systemic therapy including cyclosporine, methotrexate or Psoralen Ultra-Violet A (PUVA) Participant with active, progressive, psoriatic arthritis who have shown insufficient response to DMARD treatment
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus (SLE) For SLE Subjects SLE patients who exhibit ongoing disease activity by greater or equal to 4 SLE patients whose disease activity is controlled by administration of corticosteroids, most commonly, at least 10 mg/day of prednisone years of age or older Updated vaccinations prior to study entry Use of effective contraception for male patients before, during and up to 12 weeks after sirolimus therapy For Healthy Control Subjects years of age or older Must be matched with one of the SLE patients enrolled in the study by age, gender and ethnic origin Must not have any acute or chronic illness  For SLE Subjects Patients who are pregnant Patients with allergy or intolerance to sirolimus Patients with life-threatening manifestations of SLE Patients with proteinuria exceeding 500 mg/24 h or urine protein/creatine ratio >0.5 Patients with total cholesterol > 300 mg/dl or triglyceride > 400 mg.dl will be excluded Patients with acute infection requiring antibiotics Patients on sirolimus who develop infections and require intravenous antibiotics and fail to show clinical improvement in 5 days Patients concurrently undergoing B cell-depleting therapy, cyclophosphamide, cyclosporine, and tacrolimus Patients who have received investigational biologic B-cell depleting products within one year of study initiation
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Systemic Lupus Erythematosus High LDL Cholesterol Level SLE patients that on prednisolone more than 30 mg/day Normal liver faction: AST and ALT < 80 mg/dl Normal muscle enzyme : CPK < 100 U/L LDL cholesterol level > 100 mg/dl  Patients that was treated with pulse methylprednisolone or corticosteroid equivalent to prednisolone > 1mg/kg/day at screening Statin allergy On statin treatment before screening On cyclosporine, antifugal (azole group), antibiotics (macrolide group), rifampicin, warfarin, phenytoin Pregnancy Abnormal liver function: AST or ALT > 80 mg/dl Abnormal muscle enzyme : CPK > 300 U/L
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 19.0-60.0,  Posttraumatic Stress Disorders Outpatients between the 19-60 years of age with a diagnosis of PTSD Women must not be currently pregnant and must use a reliable method of contraception for the duration of the study Subjects must be on stable medication (4 weeks minimum) for their PTSD (symptomatic despite current treatment), must be able to provide written informed consent, must be able adequately understand and comply with the study's instructions and protocol   Those not meeting the and those not able to give informed consent Women who are currently pregnant or nursing Those at immediate risk of harming self or others; those who have a clinically significant medical illness or other significant psychiatric illness currently abusing alcohol or drugs currently being treated with an investigational medication or medication that is contraindicated with cannabinoids have a known allergy to cannabis-based products
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Metabolic Syndrome Cardiovascular Risk Factors Systemic Lupus Erythematosus Persons aged 18 and above Persons fulfill the diagnostic of the 1997 American College of Rheumatology for systemic lupus erythematosus in the patient group  a history myocardial infarction, angina or stroke
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Age > 18 years at the time of signing the informed consent form Fulfil at least 4 for SLE as defined by the American College of Rheumatology (ACR) Present with active SLE disease with at least one of the following symptoms i) Arthritis > 2 joints with pain and signs of inflammation (i.e. tenderness, swelling, or effusion) ii) Inflammatory-type skin rash iii) Oral ulcers Laboratory values as follows Hemoglobin ≥ 100 g/L Absolute neutrophil count ≥ 1.0 x 109/L Total bilirubin ≤ 1.5 x upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 x ULN  Active severe SLE flare with central nervous system (CNS) manifestations, active renal lupus, systemic vasculitis, active pericarditis, active pleuritis, active peritonitis or other SLE manifestations requiring treatment not allowed by the study protocol Severe renal impairment (estimated or measured GFR <50%) Oral treatment with corticosteroids (>15 mg/day prednisolone or equivalent) or changes in corticosteroid dosing within 30 days prior to the first dose of study medication. This also includes intraarticular steroid injections or topical treatment for SLE symptoms. Inhaled or topical steroids may be given for reasons other than SLE disease activity (such as asthma, contact dermatitis) as clinically indicated Intravenous corticosteroids within 3 months prior to the first dose of study medication Intravenous cyclophosphamide within 6 months prior to the first dose of study medication Treatment with anti-rheumatic/immunosuppressive drugs within 3 months prior to first dose of study medication, other than the following medications at stable doses: methotrexate (≤25 mg/week), azathioprine (≤2.5 mg/kg/day), hydroxychloroquine and mycophenolate mofetil (≤3000 mg/day) B-cell depletion therapy (such as treatment with Rituximab) within 12 months prior to the first dose of study medication Potent inhibitors or inducers of CYP3A4 intravenously or orally within 14 days prior to first dose of study medication History of myocardial infarction or current uncontrolled angina, severe uncontrolled ventricular arrhythmias, symptomatic congestive heart failure, unstable angina pectoris, or electrocardiographic evidence of acute ischemia Marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >450 milliseconds
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Inflammation Systemic Lupus Erythematosus Diagnosis of systemic lupus erythematosus (SLE) Disease duration: 6 months or longer Stable, mild to moderately active systemic lupus erythematosus (SLE) Receiving stable maintenance therapy  Significant Lupus Nephritis Active central nervous system (CNS) disease Significant arterial or venous thrombosis (blood clots) within 12 months prior to trial start Body weight of 260 lbs/120 kg or more History of alcohol or substance abuse History of cancer Infections Viral infections: HIV, Hepatitis B or C, Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Varicella-Zoster Virus (VZV), or Herpes Simplex Virus (HSV-1 or HSV-2) Tuberculosis Severe systemic bacterial, viral or fungal infections within the past 12 months prior to trial start
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  SLE no administration of drugs that would potentially influence QT duration except hydroxychloroquine no history of ischemic heart disease, congestive heart failure, atrial fibrillation, bundle branch block or abnormal serum electrolytes normal resting ECG and a good-quality ECG recording to measure the QT interval  moderate or severe valve disease atrial fibrillation and other ECG abnormalities systolic left ventricular dysfunction (ejection fraction <50% or left ventricular end diastolic dimension >5.5 mm unreliable identification of the end of the T wave in the ECG and known presence of cardiac disease including hypertension, diabetes or coronary artery disease
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 10.0-45.0,  Systemic Lupus Erythematosus Sister Diagnosed with SLE Proband must be a female and have documented SLE that meets ACR criteria. SLE must be diagnosed by and including age 40 Proband must have at least one biological sister ≥ 10 years of age and ≤ 45 who is available and willing to donate a blood sample and enroll in a longitudinal study. Both full and half siblings qualify  If above are met for the proband, there are no exclusions Sister who does not have SLE Female with a full or half sister who has been documented SLE that meets ACR criteria Sister must be currently between ages ≥ 10 and ≤ 45 at the time of enrollment and not have a diagnosis of SLE Sister must be able to complete questionnaires and should be willing to donate a blood sample at baseline and follow-up Sister should communicate to the recruiter that she is willing to be followed for a period of at least two years by phone and/or internet If Sister meets there will be no exclusions
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Systemic Lupus Erythematosus Atherosclerosis Female SLE patients Age 18-60 years If premenopausal using a reliable method of contraception Clinically stable disease Taking hydroxychloroquine and up to 15mgs of prednisolone daily  Smokers Pregnancy or breast feeding Use of other immunosuppressants (hydroxychloroquine and stable dose of prednisolone up to 15 mgs daily will be permitted) Use of any investigational drug within 1 month prior to screening Acute infections 2 weeks prior to Visit 1 History of ischaemic heart disease or end stage renal disease Current signs or symptoms of severe, progressive or uncontrolled hepatic, haematological, gastroenterological, endocrine, pulmonary, cardiac or neurological disease
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Systemic Lupus Erythematosus age 18-65 Diagnosis of SLE based on ACR  presently enrolled in a yoga program osteoporosis (T score ≥ -2.5) avascular necrosis taking quinolone in the preceding 3 months taking ≥ 30 mg of prednisone daily history of joint replacement or organ transplant Persons with any pre-existing condition that would prevent attendance at the yoga classes
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Infections, Papillomavirus Subject must be female Subject must be aged 10 and over  Subject with obvious fever Subject with obvious severe acute disease Subject with hypersensitivity to any component of Cervarix® Other than above, subject who is in inappropriate conditions for vaccination
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 2.0-18.0,  Juvenile Idiopathic Arthritis Diagnosis must have been before the patient's 16th birthday Disease duration of at least 6 months before study entry Must have 5 or more joints with active arthritis Must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area [BSA] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate) May take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry Must have qualifying laboratory values at the first visit  Have known allergies, hypersensitivity, or intolerance to golimumab or similar therapeutics Are pregnant or breast-feeding, or planning a pregnancy or fathering a child within 6 months after the last study agent administration Have initiated and/or immunosuppressive therapy within 4 weeks prior to study initiation
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lupus Erythematosus Diagnosed with cutaneous lupus erythematosus and/or systemic lupus erythematosus by clinical, laboratory, and histopathological findings Ability to speak and read English or Spanish at a 6th grade reading level (a translator will be available with additional consent forms in Spanish) Ability to give written informed consent  Less than 18 years of age, since the characteristics of the disease in these subjects could be very different Due to a medication, in which its discontinuation results in the resolution of cutaneous lupus, since the characteristics of the disease in these subjects could be very different Medical conditions who do not warrant a skin biopsy Unable to give written, informed consent or undergo a skin biopsy and/or venipuncture for any other reason
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Systemic Lupus Erythematosus All SLE (Systemic Lupus Erythematosus) pregnant women (aged 18 years) before 14 weeks of gestation, with autoimmune thyroid antibodies  SLE (Systemic Lupus Erythematosus) patients already on levothyroxine. Those patients discovered to be hypothyroid who need levothyroxine as part of standard of care
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 5.0-21.0,  Systemic Lupus Erythematosus For SLE subjects: Subjects age 5-21 drawn from rheumatology clinic at Children's Hospital of Philadelphia diagnosed with SLE for at least 1 month. Also subjects with no known vertebral compression fracture of L2 For Control subjects: Subjects age 5-21. Controls will be a 50% male/female  For SLE subjects: Subjects with SLE will be excluded if they have conditions or drug exposure unrelated to SLE and known to impact growth or bone health For Control subjects: Chronic disease or syndrome known to affect growth or bone health, prematurity (<37 weeks gestation), or use of any medication known to affect growth
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Systemic lupus erythematosus Age > 18 years Serum vitamin D levels [25(OH)D] < 30 ng/mL Low to moderate active disease without modification of associated treatments  Pregnancy Serum 25(OH)D levels > 30 ng/mL Flare requiring modification of treatments
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Brain Metastases Small Cell Lung Cancer Brain metastases Age ≥ 18 years Signed informed consent Recursive Partitioning Analysis (RPA) class III patients Recursive Partitioning Analysis (RPA) class I-II patients and >3 brain metastases Patients with small cell lung cancer extended disease eligible for prophylactic Whole-Brain Radiotherapy (WBRT)  Previous whole brain radiotherapy
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Male or female of ≥18 years of age Written informed consent Diagnosis of SLE satisfying at least 4 out of the 11 ACR during the course of their illness Disease duration of at least 6 months score ≥ 6 at screening Positive test results for antinuclear antibody (ANA) (HEp-2 ANA ≥1:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (≥30 IU/mL) at screening Negative serum pregnancy test and highly effective method of contraception for woman of childbearing potential  Increase in dosing of corticosteroids within 2 weeks prior to screening Introduction of MMF within 3 months prior to TD1 or increase in dosing within 1 month before screening Change in dosing of immunosuppressants or corticosteroids during the screening period Serum IgG < 6g/L Estimated Glomerular Filtration Rate (GFR) <50 mL/min/1.73m² Urinary protein:creatinine ratio >2 mg/mg History of demyelinating disease Breastfeeding or pregnancy Legal or limited legal capacity Additional